Antibiotic research and development: Business as usual?

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1604-1607

  Harbarth, S ^a   Theuretzbacher, U ^b   Hackett, J ^c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Center For Anti Infective Agents Vienna   (Austria)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Antimicrobial agents; Clinical studies; Drug development; Economics; Global health policy; Multidrug resistance; Patient safety

Indexed keywords

ANTIBIOTIC AGENT; ARSPHENAMINE; BACITRACIN; CARBAPENEM; CEPHALOSPORIN; CHLORAMPHENICOL; CHLORTETRACYCLINE; CYCLOSERINE; DAPTOMYCIN; ERYTHROMYCIN; FOSFOMYCIN; FUSIDIC ACID; ISONIAZID; LINCOMYCIN; MONOBACTAM DERIVATIVE; NALIDIXIC ACID; NITROFURAN DERIVATIVE; NOVOBIOCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PLEUROMUTILIN; POLYMYXIN; PSEUDOMONIC ACID; RIFAMYCIN; STREPTOGRAMIN DERIVATIVE; STREPTOMYCIN; SULFONAMIDE; TRIMETHOPRIM; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG INDUSTRY; DRUG RESEARCH; GOVERNMENT; HEALTH CARE POLICY; HUMAN; MULTIDRUG RESISTANCE; PHARMACEUTICAL CARE; PUBLIC HEALTH; RISK MANAGEMENT; DRUG DEVELOPMENT; ECONOMICS; ISOLATION AND PURIFICATION; MOTIVATION; ORGANIZATION AND MANAGEMENT; PROCEDURES; RESEARCH; TRENDS;

ANTI-BACTERIAL AGENTS; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MOTIVATION; RESEARCH;

EID: 84930513816     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv020     Document Type: Article

References (14)

1. Huttner A, Harbarth S, Carlet J et al. Antimicrobial resistance: a global view from the 2013 World Healthcare-Associated Infections Forum. Antimicrob Resist Infect Control 2013; 2: 31.
2. Yoshikawa TT. Antimicrobial resistance and aging: beginning of the end of the antibiotic era? J Am Geriatr Soc 2002; 50 Suppl 7: 226-9.
3. Boucher HW, Talbot GH, Benjamin DK Jr et al. 10×'20 Progress-development of newdrugs active against Gram-negative bacilli: an update fromthe Infectious Diseases Society of America. Clin Infect Dis 2013; 56: 1685-94.
4. Huttner B, Harbarth S. Think (Gram) negative! Crit Care 2010; 14: 171.
5. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011; 24: 71-109.
6. Laxminarayan R, Powers JH. Antibacterial R&D incentives. Nat Rev Drug Discov 2011; 10: 727-8.
7. Laxminarayan R. Antibiotic effectiveness: balancing conservation against innovation. Science 2014; 345: 1299-301.
8. Kirby T. Europe to boost development of new antimicrobial drugs. Lancet 2012; 379: 2229-30.
9. Piddock LJ. The crisis of no new antibiotics-what is the way forward? Lancet Infect Dis 2012; 12: 249-53.
10. Brown ED. Is the GAIN Act a turning point in new antibiotic discovery? Can J Microbiol 2013; 59: 153-6.
11. UK Government. Prime Minister Warns of Global Threat of Antibiotic Resistance. 2014. https://www.gov.uk/government/news/prime-ministerwarns- of-global-threat-of-antibiotic-resistance.
12. Davey P, Brown E, Charani E et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013; issue 4: CD003543.
13. Huttner B, Harbarth S, Nathwani D, on behalf of the ESCMID Study Group for Antibiotic Policies (ESGAP). Success stories of implementation of antimicrobial stewardship: a narrative review. Clin Microbiol Infect 2014; 20: 954-62.
14. Mullard A. Momentum builds around new antibiotic business models. Nat Rev Drug Discov 2014; 13: 711-3.